Nothing Special   »   [go: up one dir, main page]

ATE293621T1 - Imidazolin-derivate, ihre herstellung und ihre verwendung als entzündungshemmende mittel - Google Patents

Imidazolin-derivate, ihre herstellung und ihre verwendung als entzündungshemmende mittel

Info

Publication number
ATE293621T1
ATE293621T1 AT02700268T AT02700268T ATE293621T1 AT E293621 T1 ATE293621 T1 AT E293621T1 AT 02700268 T AT02700268 T AT 02700268T AT 02700268 T AT02700268 T AT 02700268T AT E293621 T1 ATE293621 T1 AT E293621T1
Authority
AT
Austria
Prior art keywords
preparation
inflammatory agents
imidazoline derivatives
imidazoline
derivatives
Prior art date
Application number
AT02700268T
Other languages
English (en)
Inventor
Volkmar Wehner
Horst Blum
Hartmut Ruetten
Hans Ulrich Stilz
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Application granted granted Critical
Publication of ATE293621T1 publication Critical patent/ATE293621T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02700268T 2001-03-10 2002-02-23 Imidazolin-derivate, ihre herstellung und ihre verwendung als entzündungshemmende mittel ATE293621T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10111877A DE10111877A1 (de) 2001-03-10 2001-03-10 Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
PCT/EP2002/001917 WO2002072573A1 (en) 2001-03-10 2002-02-23 Imidazolidine derivatives, their preparation, and their use as antinflamatory agent.

Publications (1)

Publication Number Publication Date
ATE293621T1 true ATE293621T1 (de) 2005-05-15

Family

ID=7677184

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02700268T ATE293621T1 (de) 2001-03-10 2002-02-23 Imidazolin-derivate, ihre herstellung und ihre verwendung als entzündungshemmende mittel

Country Status (35)

Country Link
US (1) US6680333B2 (de)
EP (1) EP1373249B1 (de)
JP (1) JP4482277B2 (de)
KR (1) KR100991678B1 (de)
CN (1) CN1227248C (de)
AR (1) AR035692A1 (de)
AT (1) ATE293621T1 (de)
AU (1) AU2002233358B2 (de)
BG (1) BG108134A (de)
BR (1) BR0207981A (de)
CA (1) CA2440648C (de)
CZ (1) CZ301893B6 (de)
DE (2) DE10111877A1 (de)
DK (1) DK1373249T3 (de)
EE (1) EE05401B1 (de)
ES (1) ES2240687T3 (de)
HK (1) HK1062173A1 (de)
HR (1) HRP20030713B1 (de)
HU (1) HU228304B1 (de)
IL (2) IL157830A0 (de)
ME (1) MEP61108A (de)
MX (1) MXPA03007634A (de)
MY (1) MY129029A (de)
NO (1) NO326001B1 (de)
NZ (1) NZ528075A (de)
PE (1) PE20020904A1 (de)
PL (1) PL204622B1 (de)
PT (1) PT1373249E (de)
RS (1) RS51140B (de)
RU (1) RU2303592C2 (de)
SI (1) SI1373249T1 (de)
SK (1) SK286652B6 (de)
TW (1) TWI328587B (de)
WO (1) WO2002072573A1 (de)
ZA (1) ZA200306107B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19647380A1 (de) * 1996-11-15 1998-05-20 Hoechst Ag 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
CN1362948A (zh) * 1999-03-22 2002-08-07 奥索-麦克尼尔药品公司 3s－3－氨基－3－芳基丙酸及其衍生物的制备方法
US20070043078A1 (en) * 2003-10-10 2007-02-22 Kowa Co., Ltd. Angiogenesis inhibitor
CA2723358A1 (en) * 2008-05-05 2009-11-12 Allison B. Reiss Method for improving cardiovascular risk profile of cox inhibitors
HUE050713T2 (hu) 2010-10-25 2020-12-28 Biogen Ma Inc Módszerek az ALFA-4 integrin aktivitás eltéréseinek meghatározásához, a sVCAM ÉS/VAGY sMAdCAM szintek egymáshoz viszonyításával
CN112707874A (zh) * 2020-12-29 2021-04-27 广东中科药物研究有限公司 一种抗病毒化合物及其制备方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4009506A1 (de) 1990-03-24 1991-09-26 Hoechst Ag Hydantoinderivate
DE4126277A1 (de) 1991-08-08 1993-02-11 Cassella Ag Hydantoinderivate
JPH07506091A (ja) 1992-01-13 1995-07-06 バイオゲン　インコーポレイテッド 喘息の処置
CA2129637C (en) 1992-02-12 1999-05-04 Roy R. Lobb Treatment for inflammatory bowel disease
DE4207254A1 (de) 1992-03-07 1993-09-09 Cassella Ag 4-oxo-2-thioxoimidazolidin-derivate
DE4213634A1 (de) 1992-04-24 1993-10-28 Cassella Ag 2,4-Dioxo-imidazolidin-Derivate
DE4224414A1 (de) 1992-07-24 1994-01-27 Cassella Ag Phenylimidazolidin-derivate, ihre Herstellung und ihre Verwendung
DE4228717A1 (de) 1992-08-28 1994-03-03 Cassella Ag Imidazolidin-Derivate
JPH08505628A (ja) 1993-01-08 1996-06-18 田辺製薬株式会社 ペプチド型細胞接着阻害薬
JPH08507680A (ja) 1993-01-12 1996-08-20 バイオジェン インコーポレイテッド 組換え抗ｖｌａ４抗体分子
JP3593343B2 (ja) 1993-02-09 2004-11-24 バイオジェン インコーポレイテッド インシュリン依存型糖尿病の治療
DE4308034A1 (de) 1993-03-13 1994-09-15 Cassella Ag Neue Heterocyclen, ihre Herstellung und ihre Verwendung
DE4427979A1 (de) 1993-11-15 1996-02-15 Cassella Ag Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung
AU693143B2 (en) 1993-12-06 1998-06-25 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
CN1211123C (zh) 1994-01-25 2005-07-20 雅典娜神经科学公司 抗白细胞粘附分子vla－4的人源化抗体
CA2193828A1 (en) 1994-06-29 1996-01-11 Timothy P. Kogan Process to inhibit binding of the integrin alpha 4 beta 1 to vcam-1 or fibronectin
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
DE19515177A1 (de) 1995-04-28 1996-10-31 Cassella Ag Hydantoinderivate als Zwischenprodukte für pharmazeutische Wirkstoffe
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
ES2171768T3 (es) 1996-03-20 2002-09-16 Hoechst Ag Inhibidores de la resorcion osea y antagonistas de receptores de vitronectina.
BR9710570A (pt) 1996-07-25 2005-06-28 Biogen Inc Inibidor de adesão de células
PL323130A1 (en) 1996-11-15 1998-05-25 Hoechst Ag Application of heterocyclic compounds in production of a pharmaceutic agent, novel heterocyclic compounds and pharmaceutic agent as such
DE19647380A1 (de) 1996-11-15 1998-05-20 Hoechst Ag 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19647381A1 (de) 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
WO1998042656A1 (en) 1997-03-21 1998-10-01 Cytel Corporation Novel compounds
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
WO1999023063A1 (en) 1997-10-31 1999-05-14 Aventis Pharma Limited Substituted anilides
GB9723789D0 (en) * 1997-11-12 1998-01-07 Zeneca Ltd Chemical compounds
DE19751251A1 (de) * 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
AU3716499A (en) 1998-04-21 1999-11-08 Aventis Pharma Limited Substituted diamines and their use as cell adhesion inhibitors
DE19821483A1 (de) * 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
IL139584A0 (en) * 1998-06-30 2002-02-10 Pfizer Prod Inc Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory autoimmune and respiratory diseases
WO2000002903A1 (en) 1998-07-10 2000-01-20 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
DE19922462A1 (de) * 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate

Also Published As

Publication number Publication date
HK1062173A1 (en) 2004-10-21
MY129029A (en) 2007-03-30
CA2440648C (en) 2010-06-15
NO20033981D0 (no) 2003-09-09
PL204622B1 (pl) 2010-01-29
DE60203791D1 (de) 2005-05-25
RU2003129986A (ru) 2005-03-20
EP1373249B1 (de) 2005-04-20
AU2002233358B2 (en) 2007-03-22
IL157830A (en) 2009-05-04
CZ301893B6 (cs) 2010-07-21
NZ528075A (en) 2005-02-25
WO2002072573A1 (en) 2002-09-19
IL157830A0 (en) 2004-03-28
MXPA03007634A (es) 2003-12-04
SI1373249T1 (de) 2005-08-31
CA2440648A1 (en) 2002-09-19
PT1373249E (pt) 2005-07-29
US6680333B2 (en) 2004-01-20
DK1373249T3 (da) 2005-08-22
ES2240687T3 (es) 2005-10-16
JP2004523574A (ja) 2004-08-05
HU228304B1 (en) 2013-03-28
BG108134A (bg) 2004-09-30
HRP20030713B1 (en) 2006-02-28
PL362573A1 (en) 2004-11-02
DE60203791T2 (de) 2006-01-19
HRP20030713A2 (en) 2005-02-28
CN1496360A (zh) 2004-05-12
NO326001B1 (no) 2008-09-01
NO20033981L (no) 2003-09-09
EP1373249A1 (de) 2004-01-02
JP4482277B2 (ja) 2010-06-16
BR0207981A (pt) 2004-06-15
HUP0303455A3 (en) 2005-06-28
CN1227248C (zh) 2005-11-16
TWI328587B (en) 2010-08-11
KR100991678B1 (ko) 2010-11-04
PE20020904A1 (es) 2002-12-10
CZ20032429A3 (cs) 2003-12-17
EE05401B1 (et) 2011-04-15
EE200300436A (et) 2003-12-15
SK11262003A3 (sk) 2004-01-08
AR035692A1 (es) 2004-06-23
US20030073723A1 (en) 2003-04-17
MEP61108A (en) 2011-05-10
HUP0303455A2 (hu) 2004-03-01
YU70803A (sh) 2006-05-25
DE10111877A1 (de) 2002-09-12
ZA200306107B (en) 2004-09-01
SK286652B6 (sk) 2009-03-05
KR20030082980A (ko) 2003-10-23
RU2303592C2 (ru) 2007-07-27
RS51140B (sr) 2010-10-31

Similar Documents

Publication Publication Date Title
ATE284886T1 (de) Benzimidazolderivate, ihre herstellung und therapeutische verwendung
DE50209483D1 (de) Xanthinderivate, deren herstellung und deren verwendung als arzneimittel
ATE425979T1 (de) Neue substituierte imidazo-pyridinone und imidazo-pyridazinone, ihre herstellung und ihre verwendung als arzneimittel
DE60036803D1 (de) Arylmethyl-carbonylamino-thiazolderivate und ihre verwendung als antitumormittel
DE60139477D1 (de) 2-cyanopyrrolidin-derivate und ihre verwendung als arzneimittel
DE60209779D1 (de) Sulfonamidderivate, deren herstellung und deren verwendung als medikamente
DE60123210D1 (de) Picolinsäure-derivate und ihre verwendung als fungizide
DE50312295D1 (de) 8-ä3-amino-piperidin-1-ylü -xanthine, deren herstellung und deren verwendung als arzneimittel
ATE424202T1 (de) Substituierte 2-thio-3,5-dicyano-4-phenyl-6- aminopyridine und ihre verwendung
DE60234409D1 (de) Säuregenerator, Sulfonsäure, Sulfonsäurederivate und strahlungsempfindliche Zusammensetzung
ATE332294T1 (de) Dihydro-1,3,5-triazin-diamin-derivate und ihre therapeutische verwendung
DE60001307D1 (de) Pyridopyranoazepinderivate, ihre herstellung und therapeutische verwendung
DE60200427D1 (de) Vernetzbare Fluorelastomerzusammensetzungen, ihre Herstellung und Verwendung
ATE432701T1 (de) Indol-6-sulfonamid-derivate, ihre herstellung und ihre verwendung als 5-ht-6 modulatoren
ATE267201T1 (de) 4-(2-phenylthiazol-5-yl)1,4- diazabicyclo(3.2.2)nonanederivate, ihre herstellung und therapeutische verwendung
ATE357448T1 (de) Benzoxazinonderivative, deren herstellung und verwendung
DE602004021384D1 (de) Indol-5 -sulfonamid-derivate, ihre herstellung und verwendung als 5-ht-6 modulatoren
ATE312828T1 (de) Acylaminothiazolderivate, deren herstellung und deren therapeutische verwendung
ATE242197T1 (de) 3-amino-3-arylpropan-1-ol-derivate, deren herstellung und verwendung
ATE533768T1 (de) Imidazol-derivate, ihre herstellung und ihre verwendung
DE60321372D1 (de) 3-phenylpyridoindolderivate, ihre herstellung und verwendung
DE60144456D1 (de) DibenzoÄb,fÜazepin-Derivate und ihre Herstellung
ATE329908T1 (de) Arylethene-sulfonamid derivate, deren herstellung und deren verwendung als endothelin-antagonisten
ATE293621T1 (de) Imidazolin-derivate, ihre herstellung und ihre verwendung als entzündungshemmende mittel
ATE484503T1 (de) 2-pyrrolidin-2-yl-ä1,3,4ü -oxadiazol-derivate und ihre verwendung als antidepressiva

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1373249

Country of ref document: EP